Anzeige
Mehr »
Login
Samstag, 04.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
InnoCan Pharma: Multi-Milliarden-Wert in diesem Pennystock?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
46 Leser
Artikel bewerten:
(0)

U.S. Therapeutic Plasma Exchange Market Worth 260 Million USD by 2021

PUNE, India, July 19, 2016 /PRNewswire/ --

According to a new market research report "U.S. Therapeutic Plasma Exchange Market by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Guillain Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) - Forecasts to 2021" published by MarketsandMarkets, The U.S. therapeutic plasma exchange (TPE) market by indication is estimated to reach USD 260.0 Million by 2021, growing at a CAGR of 11% to 12% during the forecast period.

(Logo: http://photos.prnewswire.com/prnh/20160303/792302)
Browse 55 market data Tables and 10 Figures spread through 91 Pages and in-depth TOC on "U.S. Therapeutic Plasma Exchange Market"

http://www.marketsandmarkets.com/Market-Reports/us-therapeutic-plasma-exchange-market-87153046.html

Early buyers will receive 10% customization on this report.

The growing prevalence of neurological diseases; increasing adoption of TPE procedures in rare disorders such as Guillain-Barré syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Neuromylitis Optica, Thrombotic Thrombocytopenic Purpura (TTP), and Cryoglobulinaemia; and growing awareness about the increasing clinical response rate of TPE procedures in various diseases in the U.S. are driving the growth in this market segment. However, factors such as high cost of therapeutic plasma exchange procedures, lack of awareness about the TPE process, lack of skilled professionals, and risks associated with therapeutic plasma exchange procedure are restraining the growth of the U.S. Therapeutic Plasma Exchange Market to a certain extent.

Speak to our research experts:

http://www.marketsandmarkets.com/speaktoanalyst.asp?id=87153046

The U.S. therapeutic plasma exchange (TPE) market by indication is broadly segmented into neurological disorders, hematology disorders, renal disorders, autoimmune disorders, and metabolic disorders. In 2015, the neurological disorders segment accounted for the largest share of the U.S therapeutic plasma exchange market; this segment is also projected to grow at the highest CAGR during the forecast period. The growing prevalence of neurological diseases; increasing clinical response rate for therapeutic plasma exchange in Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and myasthenia gravis; and growing prevalence of multiple sclerosis in the U.S. are driving the growth in this market segment.

This study also provides information on the number of patients treated and the total number of TPE procedures performed for various diseases. Some of the major players in the U.S. Therapeutic Plasma Exchange Market are Haemonetics Corporation (U.S.), Fresenius Medical Care (Germany), Terumo BCT, Inc. (U.S.), Baxter International Inc. (U.S.), Asahi Kasei Medical Co., Ltd. (Japan), Kawasumi Laboratories Inc. (Japan), B. Braun Melsungen AG (Germany), and HemaCare Corporation (U.S.).

Browse Related Reports:

Apheresis Market by Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis), Procedure (Therapeutic Apheresis, Donor Apheresis/Apheresis Blood Donation), and Technology & by Product - Global Forecast to 2020

http://www.marketsandmarkets.com/Market-Reports/apheresis-market-950.html

Plasma Fractionation Market by Product (Albumin, Immunoglobulin, Factor VIII, Protease Inhibitors), Application (Neurology, Immunology, Hematology, Critical Care) & by End-user (Hospitals, Clinical Research Laboratories) - Global Forecast to 2019

http://www.marketsandmarkets.com/Market-Reports/plasma-fractionation-market-93798284.html

About MarketsandMarkets:

MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.

M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Subscribe Reports from Healthcare Domain @ http://www.marketsandmarkets.com/Subscription.html

Contact:
Mr. Rohan
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
1-888-600-6441
Email: sales@marketsandmarkets.com

Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/medical-devices

Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets


Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2016 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.